Key facts
- It has raised $10.5M; the latest was Accelerator/Incubator in Nov 2025.
- Notable investors include Y Combinator, Bpifrance, La French Tech, Omnes Capital, Aloe Private Equity — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for WhiteLab Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for WhiteLab Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About WhiteLab Genomics
Developer of a gene and cell therapy platform designed for analyzing and optimizing genomic medicine. The company's platform processes biological, technical, and experimental datasets, integrating artificial intelligence-driven molecular design, predictive analytics, and structured evaluation frameworks, enabling researchers and pharmaceutical companies to accelerate drug development, refine gene therapy strategies, and improve the precision and effectiveness of genomic treatments.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2019
- Employees
- 48
- Website
- whitelabgx.com/
- Ownership
- Privately Held (backing)
WhiteLab Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in WhiteLab Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on WhiteLab Genomics in its N-PORT filings yet. We sweep new filings monthly.